Literature DB >> 15375776

CD26/dipeptidyl peptidase IV and its role in cancer.

B Pro1, N H Dang.   

Abstract

CD26/Dipeptidyl Peptidase IV (DPPIV) is a 110-kDa glycoprotein that is expressed on numerous cell types and has multiple biological functions. A key facet of CD26/DPPIV biology is its enzymatic activity and its physical and functional interaction with other molecules. The substrates of CD26/DPPIV are proline-containing peptides and include growth factors, chemokines, neuropeptides, and vasoactive peptides. DPPIV plays an important role in immune regulation, signal transduction, and apoptosis. Furthermore, CD26 appears to play an important role in tumor progression. In the present review, we summarize key aspects of CD26/DPPIV involvement in tumor biology and its potential role in cancer development and behavior.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15375776     DOI： 10.14670/HH-19.1345

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN： 0213-3911            Impact factor:   2.303


  32 in total

1.  Expression levels of seprase/FAPα and DPPIV/CD26 in epithelial ovarian carcinoma.

Authors:  Mengzhen Zhang; Liwei Xu; Xiaoling Wang; Beibei Sun; Juan Ding
Journal:  Oncol Lett       Date:  2015-04-27       Impact factor: 2.967

Review 2.  Biomarkers and signaling pathways of colorectal cancer stem cells.

Authors:  Danysh Abetov; Zhanar Mustapova; Timur Saliev; Denis Bulanin
Journal:  Tumour Biol       Date:  2015-02-14

3.  Impaired glucose metabolism treatment and carcinogenesis.

Authors:  Artur Matyszewski; Anna Czarnecka; Maciej Kawecki; Piotr Korzeń; Ilan J Safir; Wojciech Kukwa; Cezary Szczylik
Journal:  Oncol Lett       Date:  2015-06-04       Impact factor: 2.967

4.  Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.

Authors:  Haipeng Shao; Constance M Yuan; Liqiang Xi; Mark Raffeld; John C Morris; John E Janik; Maryalice Stetler-Stevenson
Journal:  Am J Clin Pathol       Date:  2010-04       Impact factor: 2.493

5.  A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers.

Authors:  Azka Ali; Alejandra Fuentes; William Paul Skelton; Yu Wang; Susan McGorray; Chintan Shah; Rohit Bishnoi; Long H Dang; Nam H Dang
Journal:  Mol Clin Oncol       Date:  2018-11-13

6.  The dietary flavonoid apigenin enhances the activities of the anti-metastatic protein CD26 on human colon carcinoma cells.

Authors:  Emilie C Lefort; Jonathan Blay
Journal:  Clin Exp Metastasis       Date:  2011-02-05       Impact factor: 5.150

7.  CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12.

Authors:  Yan-Xi Sun; Elisabeth A Pedersen; Yusuke Shiozawa; Aaron M Havens; Younghun Jung; Jingcheng Wang; Kenneth J Pienta; Russell S Taichman
Journal:  Clin Exp Metastasis       Date:  2008-06-18       Impact factor: 5.150

8.  Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.

Authors:  Adolfo Varona; Lorena Blanco; Itxaro Perez; Javier Gil; Jon Irazusta; José I López; M Luz Candenas; Francisco M Pinto; Gorka Larrinaga
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

9.  Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer.

Authors:  Arpi Nazarian; Kevin Lawlor; San San Yi; John Philip; Mousumi Ghosh; Mariana Yaneva; Josep Villanueva; Alan Saghatelian; Melissa Assel; Andrew J Vickers; James A Eastham; Howard I Scher; Brett S Carver; Hans Lilja; Paul Tempst
Journal:  Mol Cell Proteomics       Date:  2014-07-23       Impact factor: 5.911

10.  Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours.

Authors:  Osamu Dohi; Haruo Ohtani; Masahito Hatori; Elichi Sato; Masami Hosaka; Hiroshi Nagura; Eiji Itoi; Shoichi Kokubun
Journal:  Histopathology       Date:  2009-10       Impact factor: 5.087
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.